<DOC>
	<DOC>NCT02233894</DOC>
	<brief_summary>Study to obtain further information on the tolerability and efficacy of Atrovent速 inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice</brief_summary>
	<brief_title>Post-marketing Surveillance of Atrovent速 Inhalets in Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Patients of both genders older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease Only patients who have not been treated with Atrovent速 within the last year are to be considered for inclusion Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent速 metered dose inhaler</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>